

Spring 2005

- 2 Letter from Rick Doblin, MAPS President**
-
- 3 MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder: An Update**
By Michael Mithoefer, MD
-
- 4 MAPS' Medical Marijuana Research Efforts**
By Rick Doblin, PhD
-
- 6 MDMA-Assisted Psychotherapy in the Treatment of Anxiety in Advanced Cancer Patients**
By John Halpern, MD
-
- 7 MDMA and Basic Research: Issues within and Beyond Therapeutic Applications**
By Ilsa Jerome, PhD
-
- 13 Neurocognitive Profile of Long Term Ecstasy Users: Proposed Research**
By Philipp Ruessli
-
- 14 Making Connections: MDMA Research on Mechanisms of Affiliation and Trust**
By Alan Fiske, PhD
-
- 17 Why I Support the Pill Testing Program (and you should, too)**
By Adam Wiggins
-
- 18 LSD and Psilocybin in the Treatment of Cluster Headaches**
By R. Andrew Sewell, MD
-
- 19 Ayahuasca/EEG Research Progress Report and Invitation to Donate**
By Frank Echenhoffer, PhD
-
- 21 Ibogaine in the 21st Century: Boosters, Tune-ups and Maintenance**
By Patrick K. Kroupa and Hattie Wells
-
- 25 Ibogaine Outcome Study Progress Report**
By Valerie Mojeiko
-
- 27 A Psychedelic Neurochemistry of Time**
By Kim A. Dawson, PhD
-
- 30 Toward a Psychospiritual Understanding of Psychedelic Therapy: A Dissertation**
By Sean G. House, PhD
-
- 32 Heffter Research Institute: Update Spring 2005**
By Dave Nichols, PhD
-
- 34 The MAPS Online Benefit Auction**
-
- 35 The Albert Hofmann Foundation Report**
By Myron Stolaroff
-
- 37 Reducing Harm and Enhancing Benefit: A Report on MAPS at Burning Man 2004**
By Brandy Doyle
-
- 41 Letters to MAPS**
-
- 43 Membership/Staff Pages**

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist researchers worldwide to design, fund, conduct, obtain governmental approval for, and report on psychedelic research in humans. Founded in 1986, **MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations.** MAPS is focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, **with the goal of eventually gaining government approval for their medical uses.** Interested parties wishing to copy any portion of this publication are encouraged to do so and are kindly requested to credit MAPS and include our address. The *MAPS Bulletin* is produced by a small group of dedicated staff and volunteers. **Your participation, financial or otherwise, is welcome.**

©2005 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS)
2105 Robinson Avenue,
Sarasota, FL 34232
Phone: 941-924-6277 or 888-868-MAPS
Fax: 941-924-6265
E-mail: askmaps@maps.org
Web: www.maps.org

Cover art by Pablo Rojas



Edited by Rick Doblin and
Brandy Doyle
Layout by phred sansbury
ISSN 1080-8981
Printed on recycled paper